ArticleFrontiers in psychiatry2026
Exploring which symptom should be targeted first in the comorbidity of anxiety and depression among adolescents with nomophobia: insight from a simulation network analysis.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To identify central and bridge symptoms linking anxiety and depression and to determine intervention-priority symptoms using simulation in Chinese college students with nomophobia. Methods: A cross-sectional online survey recruited 1, 638 college students in China who met at least mild criteria for nomophobia. Depressive and anxiety symptoms were assessed with the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7). Ising networks were estimated for depression, anxiety, and their comorbidity. Expected influence and bridge expected influence were computed, and accuracy and stability were examined via nonparametric and case-dropping bootstraps. Network Intervention simulated analysis, symptom-specific alleviating and aggravating interventions to rank targets. Results: Motor agitation/retardation (PHQ-8) and restlessness (GAD-5) were the most central symptoms in the depression and anxiety networks and remained central in the comorbidity network. Irritability (GAD-6) and feeling afraid (GAD-7) showed the highest bridge centrality, linking anxiety with depressive symptoms. NIRA indicated that reducing fatigue/low energy (PHQ-4) and excessive worry (GAD-3) would yield the largest decreases in overall network activation, whereas activating suicidal ideation (PHQ-9) and restlessness (GAD-5) would most strongly aggravate the network. Bootstrap results supported acceptable accuracy and stability (e.g., EI CS-C ≈.67 for depression;.60 for anxiety; bridge EI CS-C ≈.44 in the comorbidity network). Conclusions: Symptom-level analysis highlights actionable leverage points in nomophobia-related comorbidity. Longitudinal and experimental studies are warranted to confirm causal pathways and validate network-informed treatment sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.